Sláinte Healthcare has announced the appointment of its new Chief Financial Officer and Board Member, Mr. Declan Daly. At Sláinte Healthcare, Declan will be responsible for managing the financial oversight of the Company as it continues to grow and expand its operations worldwide.

Commenting on the appointment, Andrew Murphy Chief Executive of Sláinte Healthcare said: “Declan brings with him over 16 years’ experience in senior finance and executive roles in the healthcare and biotechnology industries.  He will be an asset to Sláinte Healthcare as we continue with our aggressive global growth strategy over the next three years.”

Prior to taking up his position at Sláinte Healthcare, Declan spent almost eight years with the global healthcare company, INAMED Corporation (IMDC: NASDAQ).  He joined INAMED in 1998 as Director of Finance and Administration of their Irish subsidiary and quickly moved to more senior financial roles, culminating in the role of Executive Vice President and CFO of INAMED Corporation based in California, USA.  During his time in INAMED, Declan was instrumental in executing the $3.3 billion sale of INAMED to Allergan, Inc. (AGN: NYSE) in April 2006.

Subsequent to the sale of INAMED, Declan then joined Fibrocell Science, Inc. (NYSE MKT: FSC), a biologics company based in Pennsylvania, USA, where he spent eight years.  Here, Declan held a number of positions including Chief Executive Officer, Chief Operating Officer, Chief Financial Officer and Director.  He was pivotal in the growth of Fibrocell from a small, aesthetics-focused entity to an NYSE MKT listed company.

Declan began his career in PriceWaterhouseCoopers in Dublin and subsequently worked for the Company in London and BDO in Dublin.  A fellow of the institute of Chartered Accountants in Ireland, Declan holds a Bachelor of Science degree in Management Science and Industrial System Studies from Trinity College, Dublin and a Professional Diploma in Accounting from Dublin City University.